Nov 2 (Reuters) - ISR Immune System Regulation Holding AB
(publ) ISR.ST :
* ENTERS INTO LOI WITH BUMIVAC VENTURES SDN BHD IN MALAYSIA
* LOI FOR DEVLOPMENT, DISTRIBUTION OF ISR'S NOSE SPRAY
VACCINE
AGAINST SARS-COV-2 VIRUS IN MALAYISA, OTHER AGREED COUNTRIES
* BUMIVAC TO COMMITT TO FUND NECESSARY STUDIES TO PRODUCE
350,000
DOSES OF NASAL SPRAY VACCINE BY AUG 1, 2022, FOR PHASE III
CLINICAL TRIAL
Source text for Eikon: ID:nWkr5MKl1W
Further company coverage: ISR.ST
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))